[go: up one dir, main page]

MXPA02009237A - Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma. - Google Patents

Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma.

Info

Publication number
MXPA02009237A
MXPA02009237A MXPA02009237A MXPA02009237A MXPA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A
Authority
MX
Mexico
Prior art keywords
methods
apomorphine
plasma concentration
sexual dysfunction
concentration levels
Prior art date
Application number
MXPA02009237A
Other languages
English (en)
Inventor
Thomas L Reiland
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of MXPA02009237A publication Critical patent/MXPA02009237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Se describe metodos para administrar apomorfina a un paciente para tratar disfunciones sexuales, al mismo tiempo que se reduce los efectos colaterales indeseables. En los metodos se alcanza una concentracion de apomorfina en el plasma del paciente hasta de 10 nanogramos por mililitro. Ventajosamente se puede obtener esta concentracion experimentando emesis menos del 15 por ciento de los pacientes asi tratados. Los metodos de administracion son intranasalmente, por inhalacion a los pulmones o por ingestion oral.
MXPA02009237A 2000-03-20 2001-03-14 Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma. MXPA02009237A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19054000P 2000-03-20 2000-03-20
PCT/US2001/040294 WO2001074358A1 (en) 2000-03-20 2001-03-14 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Publications (1)

Publication Number Publication Date
MXPA02009237A true MXPA02009237A (es) 2004-04-05

Family

ID=22701756

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009237A MXPA02009237A (es) 2000-03-20 2001-03-14 Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma.

Country Status (18)

Country Link
US (1) US20020006933A1 (es)
EP (1) EP1265609A4 (es)
JP (1) JP2003533441A (es)
KR (1) KR20030012852A (es)
CN (1) CN1315177A (es)
AU (1) AU2001253854A1 (es)
BG (1) BG107185A (es)
BR (1) BR0005797A (es)
CA (1) CA2403791A1 (es)
CZ (1) CZ20023427A3 (es)
HU (1) HUP0301828A3 (es)
IL (1) IL151615A0 (es)
MX (1) MXPA02009237A (es)
NO (1) NO20024442L (es)
PL (1) PL365854A1 (es)
SK (1) SK15112002A3 (es)
WO (1) WO2001074358A1 (es)
ZA (1) ZA200207113B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
WO2002062315A1 (en) * 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
JP4493594B2 (ja) * 2003-03-04 2010-06-30 田辺三菱製薬株式会社 粉末経鼻投与製剤
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2004089374A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CN107693486A (zh) * 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
WO2014205031A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
DK1035833T3 (da) * 1997-12-02 2006-01-09 Archimedes Dev Ltd Sammensætning til nasal indgivelse
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
WO1999066909A2 (en) * 1998-06-22 1999-12-29 Univ Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
HUP0301828A3 (en) 2006-02-28
WO2001074358A1 (en) 2001-10-11
ZA200207113B (en) 2004-01-28
EP1265609A4 (en) 2005-02-09
BG107185A (bg) 2003-05-30
AU2001253854A1 (en) 2001-10-15
US20020006933A1 (en) 2002-01-17
IL151615A0 (en) 2003-04-10
CN1315177A (zh) 2001-10-03
BR0005797A (pt) 2001-10-16
NO20024442L (no) 2002-11-20
PL365854A1 (en) 2005-01-10
CZ20023427A3 (cs) 2003-11-12
CA2403791A1 (en) 2001-10-11
HUP0301828A2 (hu) 2003-09-29
JP2003533441A (ja) 2003-11-11
KR20030012852A (ko) 2003-02-12
SK15112002A3 (sk) 2003-06-03
EP1265609A1 (en) 2002-12-18
NO20024442D0 (no) 2002-09-17

Similar Documents

Publication Publication Date Title
MXPA02009237A (es) Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma.
MXPA00007447A (es) Tratamiento de disfuncion sexual femenina.
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
ZA200107920B (en) Apomorphine and sildenafil composition.
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2003079979A3 (en) Method for treating congestive heart failure
AU6323001A (en) Treatment of acute coronary syndrome with glp-1
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
BE2012C040I2 (es)
JP2002523370A5 (es)
WO2005089448A3 (en) Administration of cisplatin by inhalation
IL173346A0 (en) Treatment of dependence withdrawal
ZA200609266B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin
MD1875G2 (ro) Metodă de tratament al hepatitei virale acute B
CA2398264A1 (en) Use of desloratadine for treating allergic and inflammatory conditions
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
UY27037A1 (es) Composición de apomorfina para tratar la disfunción sexual con niveles específicos de concentración en plasma
MXPA03000088A (es) Herramienta de impacto con extremo de accionamiento desprendible.
RU2002116988A (ru) Способ лечения хронических обструктивных болезней легких
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2005097102A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
UA6738A (uk) Спосіб лікування бронхообструктивного синдрому у хворих на бронхіальну астму та хронічний обструктивний бронхіт
RU2006146071A (ru) Средство для устранения фактора циркуляторной дисфункции
WO2002058703A3 (en) The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers